HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP): Case based discussion of risk factors, clinical, and therapeutic considerations
Authors:
- 19 March 2024
- journal article
- review article
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 459, 122973
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSPAnnals of Clinical and Translational Neurology, 2021
- Effectiveness of Daily Prednisolone to Slow Progression of Human T-Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis: A Multicenter Retrospective Cohort StudyNeurotherapeutics, 2017
- Spinal cord anteroposterior atrophy in HAM/TSP: Magnetic resonance imaging and neuropathological analysesJournal of the Neurological Sciences, 2017
- HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP): A comparative study to identify factors that influence disease progressionJournal of the Neurological Sciences, 2016
- HTLV-1-assoziierte Myelopathie/tropische spastische ParapareseDer Nervenarzt, 2012
- Human T cell lymphotropic virus type 1 (HTLV‐1) proviral load of HTLV‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients according to new diagnostic criteria of HAM/TSPJournal of Medical Virology, 2011
- Natural History of Human T-Lymphotropic Virus 1–Associated MyelopathyArchives of Neurology, 2006
- MRI contributes to the differentiation between MS and HTLV-I associated myelopathy in British Columbian coastal natives.Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2003
- HTLV-I ASSOCIATED MYELOPATHY, A NEW CLINICAL ENTITYThe Lancet, 1986
- ANTIBODIES TO HUMAN T-LYMPHOTROPIC VIRUS TYPE-I IN PATIENTS WITH TROPICAL SPASTIC PARAPARESISThe Lancet, 1985